$PMCB “After what can only be described as a landmark moment in PharmaCyte’s history, we are excited to report on what was a positive pre-IND meeting with the U.S. FDA. We made excellent progress and received good advice and guidance toward the goal of filing our IND. We now have a clear path forward, and we will use this upcoming shareholder call to lay out that path for analysts, shareholders and the public.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.